A prospective Crossover Triple-blind Controlled Trial on the Safety and Efficacy of Iranian Recombinant FVIII (Safacto) versus Plasma Derived FVIII A pilot study
Journal Title: Iranian Journal of Blood and Cancer - Year 2015, Vol 7, Issue 4
Abstract
Background: Considering the increasing number of patients with hemophilia and infrastructure requirements for a comprehensive approach, development of a recombinant factor has become a milestone. The objective of this study was to assess the safety, efficacy and non inferiority of Safacto (Recombinant factor VIII) compared with plasma-derived factor in the treatment of hemophilia A. Methods: 10 patients with severe hemophilia A were enrolled in this study. Each patient was treated by a 40-50 IU/kg infusion of either plasma derived or recombinant factor VIII after initiation of each of 4 consecutive hemarthrosis episodes in a triple-blind prospective crossover permuted block randomizing method. Clinical efficacy scale score and in vivo recovery of factor VIII was assessed in each of the treated bleeding episodes. Any adverse event was also recorded. Results: The mean±SD level of factor VIII in the plasma versus recombinant groups was 111.5±39 and 115±39, respectively without any significant difference. Response scaling method which assessed pain and range of motion revealed equalized scores along with in vivo recovery, hence treatment success rate was comparable in both groups. One non-recurring, mild skin rash reaction occurred simultaneous with the administration of plasma derived factor. Conclusion: Safacto (r-FVIII) is safe and effective and non-inferior to plasma derived factor VIII in the treatment of hemophilia A related bleeding events.
Authors and Affiliations
Peyman Eshghi, Hassan Abolghasemi, Fatemeh Malek, Majid Naderi, Yunes Panahi, Behnaz Habibpanah, E Fatohlahzadeh, F Gorji
Keywords
Related Articles
- EP ID EP281501
- DOI -
- Views 94
- Downloads 0
Detection of Factor VIII Inhibitors in Hemophilia A Patients
Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence...
Codon 72 Polymorphism of p53 Gene and Hematologic Manifestations in Patients with Systemic Lupus Erythematosus
Background: Systemic lupus erythematosus is a systemic autoimmune disorder with unclear etiology. The importance of some genes in the development of systemic lupus erythematosus has been implicated. The gene polymorphism...
Main Determinants of Severe Neutropenia in Patients with Solid Tumors Receiving Adjuvant Chemotherapy
Background:Chemotherapy-induced neutropenia as a major toxicity of systemic chemotherapy is commonly associated with substantial mortality and morbidity, and thus identifying its determinants is necessary. This study was...
Hereditary Spherocytosis among Neonates with Jaundice in Bandar Abbas, South Iran
Background: Neonates affected by hereditary spherocytosis may suffer from significant jaundice. This study was conducted on neonates with jaundice hospitalized at the Children’s Hospital in Bandar Abbas, South Iran, to d...
Bone Involvement in Neuroblastoma
This article has no abstract.